Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Xevinapant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005443/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN
    Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005018/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant
    Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant

    01 Oct 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/debiopharm-launches-trilynx---a-large-scale-phase-iii-clinical-trial-to-further-evaluate-xevinapant-in-the-treatment-of-head--neck-cancer-301143930.html

    PRNEWSWIRE
    01 Oct 2020
    Share Share